Sugi Predict

Sugi Predict / Compounds / SCHEMBL82230

SCHEMBL82230

SCHEMBL82230

FC(F)(F)c1ccc(Cl)c(I)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.47
▸ PDE2A O00408 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.41
▸ MCL1 Q07820 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 1/20 0.39
▸ AHR P35869 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ ADRA2A P08913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL81273 0.82 PDE2A (0.48) NOTUMPDE2AALDH1A1MEN1KMT2A
SCHEMBL31615153 0.82 PDE2A (0.48) NOTUMPDE2AALDH1A1MEN1KMT2A
SCHEMBL980201 0.78 TSHR (0.61) PDE2AALDH1A1MEN1KMT2ATSHR
SCHEMBL29402881 0.78 TSHR (0.61) PDE2AALDH1A1MEN1KMT2ATSHR
SCHEMBL7863217 0.78 PTPN5 (0.41) NOTUMALDH1A1TSHR
SCHEMBL1506566 0.77 ALDH1A1 (0.41) NOTUMALDH1A1MEN1KMT2ATSHR
Ammonia Solution, Strong SCHEMBL28020319 0.76 TSHR (0.58) PDE2AALDH1A1MEN1KMT2ATSHR
SCHEMBL19785385 0.76 PDE2A (0.47) PDE2AALDH1A1MEN1KMT2ATSHR
Water SCHEMBL27662828 0.76 PDE2A (0.43) PDE2AALDH1A1MEN1KMT2ATSHR
SCHEMBL1040760 0.74 CES2 (0.50) NOTUMPDE2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2025-04-10 — — US disclosed
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors GENENTECH, INC. (US) 2025-01-28 — — US disclosed
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-08-31 — — US disclosed
US-20220081423-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-03-17 — — US disclosed
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2021-07-15 — — US disclosed
CN-107849044-B Triaza-spirodecanones as DDR1 inhibitors 豪夫迈·罗氏有限公司 2021-06-25 — — CN disclosed
US-11028075-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-06-08 — — US disclosed
EP-3797101-A1 PYRIDIDNE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-03-31 — — EP disclosed
CN-112368274-A Pyridine-sulfonamide derivatives as sodium channel inhibitors 豪夫迈·罗氏有限公司 2021-02-12 — — CN disclosed
EP-3317279-B1 TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS HOFFMANN LA ROCHE (CH) 2021-01-27 — — EP disclosed
CN-1328551-A Process for preparing 4-substituted benzopyran derivatives CHUGAI PHARMACEUTICAL CO LTD (JP) 2001-12-26 — — CN disclosed
EP-0870747-B1 Method of making m-chlorobenzotrifluoride OCCIDENTAL CHEM CO (US) 2001-11-28 — — EP disclosed
WO-2001066553-A2 NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS METABASIS THERAPEUTICS, INC. (US) 2001-09-13 — — WO disclosed
EP-1120412-A1 PROCESSES FOR THE PREPARATION OF 4-SUBSTITUTED BENZOPYRAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-08-01 — — EP disclosed
WO-2001046146-A1 NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2001-06-28 — — WO disclosed
EP-0870747-A1 Method of making m-chlorobenzotrifluoride Occidental Chemical Corporation (US) 1998-10-14 — — EP disclosed
US-4977178-A Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1990-12-11 — — US disclosed
US-4879391-A 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents PFIZER INC. (US) 1989-11-07 — — US disclosed
US-4861880-A 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1989-08-29 — — US disclosed
US-4476307-A Heteroylidene indolone compounds PFIZER INC. (US) 1984-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220081423-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF TRPV1, HCN4, TRPA1 NOTUM 2338/4885PDE2A 1022/4885ALDH1A1 1075/4885
US-20230271988-A1 METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE HPD, TALDO1, OGG1 NOTUM 124/4885PDE2A 4809/4885ALDH1A1 1554/4885
US-11028075-B2 Therapeutic compounds and methods of use thereof TRPV1, HCN4, TRPA1 NOTUM 2338/4885PDE2A 1022/4885ALDH1A1 1075/4885
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors SCN1B, CACNA1A, SCN1A NOTUM 3757/4885PDE2A 1041/4885ALDH1A1 3192/4885
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS SCN1B, CACNA1A, SCN1A NOTUM 3855/4885PDE2A 958/4885ALDH1A1 3086/4885
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF F12, REN, ZYX NOTUM 2494/4885PDE2A 1303/4885ALDH1A1 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.